Volume 10, Number 3, March 2004

Patient Data, Early SARS Epidemic, Taiwan

Po-Ren Hsueh,* Pei-Jer Chen,* Cheng-Hsiang Hsiao,* Shiou-Huei Yeh,† Wern-Cherng Cheng,* Jiun-Ling Wang,* Bor-Luen Chiang,* Shan-Chwen Chang,* Feng-Yee Chang,‡ Wing-Wai Wong,§ Chuan-Liang Kao,* Pan-Chyr Yang,* and the SARS Research Group of National Taiwan University College of Medicine and National Taiwan University Hospital
*National Taiwan University College of Medicine, Taipei, Taiwan; †National Health Research Institute, Taipei, Taiwan; ‡Tri-service General Hospital, Taipei, Taiwan; and §Veterans General Hospital-Taipei, Taiwan

Figure 2. Timeline of therapeutic modalities used in 10 patients with severe acute respiratory syndrome (SARS). IVIG, intravenous immunoglobulin (1 g/kg/d for 2 days). IV corticosteroid, intravenous methylprednisolone (500 mg every day for 3 days, followed by 40 mg every 8 h in patient 9 or 40 mg every 8 h in other patients for 4 to 5 days and then tapered for 1 to 2 weeks). The dosage of oral ribavirin was 2,000 mg initially, then 600 mg every 12 h (or 2,000 mg every day) for 10 days and 0.8 mg/kg every day for inhalational use. Thick arrow, date of discharge.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed February 19, 2004

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention